Cytokinetics
CYTK
147 hedge funds and large institutions have $658M invested in Cytokinetics in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 59 increasing their positions, 39 reducing their positions, and 16 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 39
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
13% more capital invested
Capital invested by funds: $584M → $658M (+$73.8M)
4% more funds holding
Funds holding: 142 → 147 (+5)
5% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $11.2M
0.61% more ownership
Funds ownership: 93.13% → 93.75% (+0.61%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$43.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$7.97M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$41.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.5M |
| 3 |
Millennium Management
New York
|
-$13.8M |
| 4 |
BlackRock
New York
|
-$5.56M |
| 5 |
Morgan Stanley
New York
|
-$5.17M |
CYTK Hedge Fund Activity: Q1 2020 in Review
147 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2020, worth a combined $658M — up 13% from $584M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CYTK positions and 16 closed out — a net gain of 8 holders — while 59 added to existing stakes and 39 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $43.8M. The largest seller was BVF Inc, cutting an estimated $41.7M.
- 147 institutional investors held Cytokinetics (CYTK) as of Q1 2020, up from 142 in Q4 2019.
- Funds reported $658M of Cytokinetics stock for Q1 2020, up 13% quarter-over-quarter.
- 24 funds opened new Cytokinetics positions in Q1 2020 and 16 closed out, a net change of +8 holders.
- The largest Cytokinetics buyer in Q1 2020 was Consonance Capital Management, an estimated $43.8M added.
- The largest Cytokinetics seller in Q1 2020 was BVF Inc, an estimated $41.7M sold.
Based on aggregated 13F filings for Q1 2020.